1-20 of 182
Richard R Furman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK C481S -Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Ramon Massoni-Badosa, Joshua S. Schiffman, Barun Pradhan, Rebecca M. Murray, Andrew H. Lipsky, Debra Van Egeren, Danny Luan, Shirley Chen, Ronan Chaligne, Kai Beattie, Alyssa Indart, Nada Chraiki, Neville Dusaj, Erica B. Bhavsar, Chelston Ang, Anna S. Nam, Federico Gaiti, Paulina Chamely, Nathaniel D. Omans, Preeti Trisal, Anita K. Gandhi, Kyu-Tae Kim, Rafael Schulman, Franco Izzo, Gavriel Mullokandov, Chingiz Underbayev, Jan A. Burger, Adrian Wiestner, Elisa Ten Hacken, John N. Allan, Jennifer A. Woyach, Richard R. Furman, Dan A. Landau
Journal: Blood
Blood (2024) 144 (Supplement 1): 4610.
https://doi.org/10.1182/blood-2024-205727
Published: 2024
Journal Articles

Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience

Theresia Akhlaghi, Jose Fernandez-Rengifo, Mateo Mejia Saldarriaga, Sarah C. Rutherford, Cara Rosenbaum, Jorge Monge, Peter Martin, John N. Allan, Richard R. Furman, Ruben Niesvizky, Mark Bustoros
Journal: Blood
Blood (2024) 144 (Supplement 1): 6350.
https://doi.org/10.1182/blood-2024-210059
Published: 2024
Journal Articles

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Justin D. Kaner, Danny Luan, Franco Castillo Tokumori, John-William Sidhom, Jose Fernandez-Rengifo, Samantha Gerson, Matthew Whitcomb, Molly Vallon, Ellen K. Ritchie, Michael Samuel, Jonathan Canaani, Michal Bar-Natan, Erin Mulvey, Peter Martin, Pinkal Desai, John N. Allan, Richard R. Furman, Sarah C. Rutherford, Jia Ruan, Gail J. Roboz
Journal: Blood
Blood (2024) 144 (Supplement 1): 5379.
https://doi.org/10.1182/blood-2024-210134
Published: 2024
Journal Articles

Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)

John N. Allan, Daniel Helbig, Erin Mulvey, Sarah Nazir, Sandra Stewart, Melissa L. Lapinta, Sarah C. Rutherford, Jia Ruan, John P. Leonard, Peter Martin, Richard R. Furman
Journal: Blood
Blood (2023) 142 (Supplement 1): 3285.
https://doi.org/10.1182/blood-2023-174465
Published: 2023
Journal Articles

The Characterization of Metabolic Profile and Substrates Dependencies of Richter's Syndrome Cells Open for Translational Opportunities

Matilde Micillo, Lorenzo Brandimarte, Giulia Omezzolli, Nadia Bertola, Francesco Edoardo Vallone, Andrea Iannello, Chiara Lavarello, Nicole Grinovero, Giulio Ferrero, Kevin Mellert, Peter Moller, Nicoletta Vitale, Silvia Bruno, Richard R. Furman, John N. Allan, Andrea Petretto, Silvia Deaglio, Silvia Ravera, Tiziana Vaisitti
Journal: Blood
Blood (2023) 142 (Supplement 1): 6115.
https://doi.org/10.1182/blood-2023-179164
Published: 2023
Journal Articles

Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial

Clinical Trials & Observations
John F. Seymour, John C. Byrd, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O’Brien, Jennifer R. Brown, Talha Munir, Anthony Mato, Stephan Stilgenbauer, Naghmana Bajwa, Paulo Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (8): 687–699.
https://doi.org/10.1182/blood.2022018818
Published: 2023
Includes: Supplemental data
Journal Articles

Potential Drivers of Acquired Resistance to Idelalisib in CLL Patients

Saurabh Yadav, Jasneet Khalsa, Ishwarya Murali, Richard R. Furman, Neil E. Kay, Esteban Braggio, Jennifer R. Brown
Journal: Blood
Blood (2022) 140 (Supplement 1): 12373–12374.
https://doi.org/10.1182/blood-2022-166648
Published: 2022
Journal Articles

Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Cecilia Bonolo De Campos, Chantal McCabe, Laura Ann Bruins, Daniel R. O'Brien, Sochilt Brown, Cristine Allmer, Yuan Xiao Zhu, Kari G Rabe, Sameer A. Parikh, Neil E. Kay, James R. Cerhan, Laura Z Rassenti, Richard R. Furman, J. Brice Weinberg, Danielle Brander, Marta Chesi, Susan L. Slager, Esteban Braggio
Journal: Blood
Blood (2022) 140 (Supplement 1): 4135–4136.
https://doi.org/10.1182/blood-2022-170944
Published: 2022
Journal Articles

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 6640–6641.
https://doi.org/10.1182/blood-2022-163509
Published: 2022
Journal Articles

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O'Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Piers EM Patten, Talha Munir, Krish Patel, Anna Butturini, Marianne de Borja, Min Hui Wang, Nitin Jain, William G. Wierda
Journal: Blood
Blood (2022) 140 (Supplement 1): 9865–9867.
https://doi.org/10.1182/blood-2022-159542
Published: 2022
Journal Articles

Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)

John F. Seymour, John C. Byrd, Talha Munir, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Jennifer R. Brown, Anthony R. Mato, Stephan Stilgenbauer, Thomas Fehn, Paulo Andre P. de Miranda, Kara Higgins, Ellie John, Marianne de Borja, Wojciech Jurczak, Jennifer A. Woyach
Journal: Blood
Blood (2022) 140 (Supplement 1): 7050–7052.
https://doi.org/10.1182/blood-2022-157060
Published: 2022
Journal Articles

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Richard R. Furman, William G. Wierda, Anna Schuh, Piers EM Patten, Jorge M. Chaves, Jennifer R. Brown, Talha Munir, Peter Martin, Farrukh T. Awan, Deborah M. Stephens, Paolo Ghia, Jacqueline C. Barrientos, Krish Patel, Jennifer A. Woyach, Anna Butturini, Marianne de Borja, Min Hui Wang, Susan O'Brien, John C. Byrd
Journal: Blood
Blood (2022) 140 (Supplement 1): 9873–9875.
https://doi.org/10.1182/blood-2022-162394
Published: 2022
Journal Articles

Synergistic efficacy of the dual PI3K-δ/γ inhibitor duvelisib with the Bcl-2 inhibitor venetoclax in Richter syndrome PDX models

Andrea Iannello, Nicoletta Vitale, Silvia Coma, Francesca Arruga, Amy Chadburn, Arianna Di Napoli, Carlo Laudanna, John N. Allan, Richard R. Furman, Jonathan A. Pachter, Silvia Deaglio, Tiziana Vaisitti
Journal: Blood
Blood (2021) 137 (24): 3378–3389.
https://doi.org/10.1182/blood.2020010187
Published: 2021
Includes: Supplemental data
Journal Articles

Acalabrutinib in treatment-naive chronic lymphocytic leukemia

Clinical Trials & Observations
John C. Byrd, Jennifer A. Woyach, Richard R. Furman, Peter Martin, Susan O’Brien, Jennifer R. Brown, Deborah M. Stephens, Jacqueline C. Barrientos, Stephen Devereux, Peter Hillmen, John M. Pagel, Ahmed Hamdy, Raquel Izumi, Priti Patel, Min Hui Wang, Nitin Jain, William G. Wierda
Journal: Blood
Blood (2021) 137 (24): 3327–3338.
https://doi.org/10.1182/blood.2020009617
Published: 2021
Includes: Supplemental data
Journal Articles

ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient–derived xenograft mouse models

Tiziana Vaisitti, Francesca Arruga, Nicoletta Vitale, Thanh-Trang Lee, Mira Ko, Amy Chadburn, Esteban Braggio, Arianna Di Napoli, Andrea Iannello, John N. Allan, Langdon L. Miller, Brian J. Lannutti, Richard R. Furman, Katti A. Jessen, Silvia Deaglio
Journal: Blood
Blood (2021) 137 (24): 3365–3377.
https://doi.org/10.1182/blood.2020008404
Published: 2021
Includes: Supplemental data
Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Sarah C. Rutherford, MD, John N. Allan, MD, Jia Ruan, MD PhD, Richard R. Furman, MD, Kristy Richards, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, Kseniya Gololobova, Arcania Garcia, Leandro Cerchietti, MD, Rossella Marullo, MDPhD, Zhengming Chen, PhD MPH, MS, Jennifer Santamala, PharmD, Tsiporah B. Shore, MD, Adrienne A. Phillips, MD MPH, Sebastian Mayer, MD, Jingmei Hsu, MD, Usama Gergis, MD, Silvia Senese, Trisha Ali-Shaw, Riyaad Rahim, Koen van Besien, MD PhD, John P. Leonard, MD, Peter Martin, FRCPC, MD MS
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-134699
Published: 2020
Journal Articles

Single-Cell Multi-Omics Reveals Distinct Paths to Survival of Admixed BTK C481 Mutant Vs. Wild-Type Cells in Clinically Progressing Chronic Lymphocytic Leukemia

Andrew Lipsky, MD, Danny Luan, MPH, Shirley Chen, BSc, Ronan Chaligne, PhD, Neville Dusaj, MS, Erica B Bhavsar, BS, Chelston Ang, MS, Anna S Nam, MD, Federico Gaiti, PhD, Paulina Chamely, MSc, Nathaniel D. Omans, MS, Preeti Trisal, MS, Anita K Gandhi, PhD, Kyu-Tae Kim, PhD, Rafael Schulman, BS, Joshua S. Schiffman, PhD, Franco Izzo, PhD, Gregory Mullokandov, MD PhD, Chingiz Underbayev, MD PhD, Adrian Wiestner, MD PhD, John N. Allan, MD, Richard R. Furman, MD, Dan A. Landau, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-138374
Published: 2020
Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Samuel Yamshon, MD, Peter Martin, FRCPC, MD MS, Bijal Shah, MD, Stephen J. Schuster, MD, Paul J Christos, Dr.P.H., M.S., Amelyn Rodriguez, BSN, RN, OCN, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Sarah C. Rutherford, MD, John N. Allan, MD, John P. Leonard, MD, Jia Ruan, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-138731
Published: 2020
Journal Articles

VLS-101, a ROR1-Targeting Antibody-Drug Conjugate, Demonstrates a Predictable Safety Profile and Clinical Efficacy in Patients with Heavily Pretreated Mantle Cell Lymphoma and Diffuse Large B-Cell Lymphoma

Michael Wang, MD, Jacqueline C. Barrientos, MD, Richard R. Furman, MD, Matthew Mei, MD, Paul M. Barr, MD, Michael Y. Choi, MD, Sven de Vos, MD PhD, Avyakta Kallam, MD, Krish Patel, MD, Simon Rule, MD PhD, Kate Flanders, BS, Katti A. Jessen, PhD, Peter C. Riebling, Patricia Graham, BHSA, Lydia King, PhD, Elizabeth M. Schmidt, BSN, Brian J. Lannutti, PhD, David M. Johnson, BS, Langdon L. Miller, MD, Stephen E. Spurgeon, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
https://doi.org/10.1182/blood-2020-136373
Published: 2020
Journal Articles

Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Geffen Kleinstern, PhD, J. Brice Weinberg, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Dennis P. Robinson, Aaron D. Norman, MPH, Kari G Rabe, Celine M. Vachon, PhD, Connie E. Lesnick, Timothy G. Call, MD, Danielle M. Brander, MD, Janet E. Olson, PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Curtis A. Hanson, MD, Richard R. Furman, MD, Tait Shanafelt, MD, Susan L. Slager, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 35–36.
https://doi.org/10.1182/blood-2020-136548
Published: 2020